Biosimilars in India News: Recent Guidelines from India’s CDSCO and a Pending Case on “Biosimilar” Trastuzumab

Published date09 May 2016
Law FirmGoodwin
Subject MatterBiologics,Biosimilars,Exclusivity,Mylan Pharmaceuticals,New Guidance,Pharmaceutical Industry,Prescription Drugs,Product Labels

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT